Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.

Literature DB >> 23955641

Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.

Akira Matsuno¹, Mineko Murakami, Katsumi Hoya, Shoko M Yamada, Shinya Miyamoto, So Yamada, Jae-Hyun Son, Hajime Nishido, Fuyuaki Ide, Hiroshi Nagashima, Mutsumi Sugaya, Toshio Hirohata, Akiko Mizutani, Hiroko Okinaga, Yudo Ishii, Shigeyuki Tahara, Akira Teramoto, R Yoshiyuki Osamura.

Abstract

There have been several reports of temozolomide (TMZ) treatment of pituitary carcinomas and atypical adenomas. O(6)-methyl-guanine-DNA methyltransferase is not the sole molecule determining the sensitivity to TMZ in pituitary carcinomas and atypical adenomas. The Japan Society of Hypothalamic and Pituitary Tumors study suggests that MSH6, one of mismatch repair pathway enzyme, fulfills a contributory role to the efficacy of TMZ treatment for pituitary carcinomas and atypical adenomas. The preserved MSH6 function might be essential for the responsiveness to TMZ treatment in pituitary carcinomas and atypical adenomas.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2013 PMID： 23955641 DOI： 10.1007/s00795-013-0050-z

Source DB: PubMed Journal: Med Mol Morphol ISSN： 1860-1499 Impact factor: 2.309

83 in total

Review 1. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

Authors: A K Annamalai; A F Dean; N Kandasamy; K Kovacs; H Burton; D J Halsall; A S Shaw; N M Antoun; H K Cheow; R W Kirollos; J D Pickard; H L Simpson; S J Jefferies; N G Burnet; M Gurnell
Journal: Pituitary Date: 2012-09 Impact factor: 4.107

2. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors: K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal: Neurosurgery Date: 1996-04 Impact factor: 4.654

3. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.

Authors: Mineko Murakami; Akiko Mizutani; Shuichiro Asano; Hideki Katakami; Yoshinori Ozawa; Kazuto Yamazaki; Yasuo Ishida; Koji Takano; Hiroko Okinaga; Akira Matsuno
Journal: Neurosurgery Date: 2011-06 Impact factor: 4.654

Review 4. Repair of O(6)-alkylguanine by alkyltransferases.

Authors: A E Pegg
Journal: Mutat Res Date: 2000-04 Impact factor: 2.433

5. Pituitary carcinoma presenting with multiple metastases: case report.

Authors: Aslan Guzel; Mehmet Tatli; Senem Senturk; Ebru Guzel; Suleyman Rustu Cayli; Aydin Sav
Journal: J Child Neurol Date: 2008-12 Impact factor: 1.987

6. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

Authors: Maria Möllemann; Marietta Wolter; Jörg Felsberg; V Peter Collins; Guido Reifenberger
Journal: Int J Cancer Date: 2005-01-20 Impact factor: 7.396

7. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.

Authors: Netta Levin; Iris Lavon; Bracha Zelikovitsh; Dana Fuchs; Felix Bokstein; Yakov Fellig; Tali Siegal
Journal: Cancer Date: 2006-04-15 Impact factor: 6.860

8. Possible role of a radiation-induced p53 mutation in a Nelson's syndrome patient with a fatal outcome.

Authors: Emilia Modolo Pinto; Sheila A C Siqueira; Priscilla Cukier; Maria C B V Fragoso; Chin Jia Lin; Berenice Bilharinho de Mendonca
Journal: Pituitary Date: 2011-12 Impact factor: 4.107

Review 9. Molecular genetic markers as predictors of response to chemotherapy in gliomas.

Authors: Ahmed Idbaih; Antonio Omuro; François Ducray; Khê Hoang-Xuan
Journal: Curr Opin Oncol Date: 2007-11 Impact factor: 3.645

10. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

Authors: Olivier L Chinot; Maryline Barrié; Stephane Fuentes; Nathalie Eudes; Sophie Lancelot; Philippe Metellus; Xavier Muracciole; Diane Braguer; L'Houcine Ouafik; Pierre-Marie Martin; Henry Dufour; Dominique Figarella-Branger
Journal: J Clin Oncol Date: 2007-04-20 Impact factor: 44.544

6 in total

Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.

Review 1. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

2. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

3. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.

Review 4. Repair of O(6)-alkylguanine by alkyltransferases.

5. Pituitary carcinoma presenting with multiple metastases: case report.

6. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

7. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.

8. Possible role of a radiation-induced p53 mutation in a Nelson's syndrome patient with a fatal outcome.

Review 9. Molecular genetic markers as predictors of response to chemotherapy in gliomas.

10. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

1. Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.

Review 2. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.

3. Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina.

4. Pituitary Carcinoma in a Patient with an SDHB Mutation.

Review 5. The Treatment of Refractory Pituitary Adenomas.

Review 6. Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions.